Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

EMD Serono president James Hoyes joins consultants RxC

Takes up a role as executive partner at the US management consulting firm

- PMLiVE

Multichannel: the essential European revolution

Boosting the digital component in Europe's multichannel engagement strategy

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

- PMLiVE

Germany’s IQWIG ‘perplexed’ by EMA’s adaptive pathways plan

Reliance on real-world evidence questioned

- PMLiVE

Dr Robert Kim joins Apellis as chief medical officer

Brings experience from Novartis, Genentech and GSK

- PMLiVE

Managing value: Why early asset development and commercialisation are important

Realising the full value of your asset - clinically and commercially - means thinking beyond the pure scientific value, even at the very early stages of development

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

What kind of customer data are you getting?

How to collect the proper data to discover how to act next.

Anthill Agency

- PMLiVE

Parexel adds four to senior leadership team

Appoints David Godwin, Michelle Graham, Sy Pretorius and Joshua Schultz

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

Products as portfolios: positioning immuno-oncology products

The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning...

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links